Drug International Limited
Drug International Limited is a Bangladesh-based pharmaceutical manufacturer founded in 1974, producing generic medicines across oncology, cardiology, steroids, vitamins, and antibiotics, plus herbal and Unani product lines, exporting to over 37 countries worldwide.
- Company typePrivate
- Founded1974
- HeadquartersDhaka, Bangladesh
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Drug International Limited does
Drug International Limited is a Bangladesh-based pharmaceutical manufacturer founded in 1974 and incorporated as a Private Limited Company. The company researches, develops, and produces generic medicines across multiple therapeutic categories including oncology (Etoposide, Doxorubicin, Paclitaxel, Sorafenib, Hydroxyurea, Epirubicin), cardiovascular (Rivaroxaban), steroids (Methylprednisolone, Deflazacort), vitamins, and antibiotics. It also operates specialized Herbal and Unani product divisions. The company was the first in Bangladesh to formulate medicines in soft gelatin capsule form (since 1990) and holds WHO cGMP certification for its manufacturing facilities.
The company operates four manufacturing facilities in the Gazipur industrial area of Bangladesh, including a dedicated factory for herbal and Unani products. Its proprietary technology centers on WHO cGMP-compliant pharmaceutical manufacturing, including state-of-the-art oral solid dosage plants and soft gelatin capsule formulation capabilities developed since the 1980s. Modern Quality Control and Product Development laboratories support quality assurance and innovation.
Drug International Limited generates revenue through direct sales of pharmaceutical products to healthcare providers, primarily via international export channels reaching 37+ countries across South Asia, Africa, the Middle East, Southeast Asia, Eastern Europe, and Latin America. Distribution occurs through direct export sales and domestic channels within Bangladesh. The company is privately held with no disclosed institutional investors or parent company, and is led by a Founder Chairman and Managing Director.
Drug International Limited firmographics
Firmographics- Name
- Drug International Limited
- Legal name
- Drug International Limited
- Website
- https://drug-international.com
- Company type
- Private
- Founded year
- 1974
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Drug International Limited is a Bangladesh-based pharmaceutical manufacturer founded in 1974, producing generic medicines across oncology, cardiology, steroids, vitamins, and antibiotics, plus herbal and Unani product lines, exporting to over 37 countries worldwide.
- Ownership category
- akta.pro rank
Drug International Limited industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Specialty Care Pharmaceuticals (HLAIAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Drug International Limited is headquartered
LocationHeadquarters
- HQ city
- Dhaka
- HQ country
- Bangladesh
- HQ region
- Asia
Offices5 records
Markets served
Drug International Limited business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Manufacturing and Sales: Drug International Limited generates revenue through the research, development, and production of pharmaceutical products across key therapeutic categories including Oncology, Cardiology, Steroids, Vitamins, and Antibiotics.
- International Export: Revenue generated from exporting pharmaceutical products to multiple countries across South Asia, Africa, Middle East, and Southeast Asia.
- Herbal Products Division: Revenue from herbal product line combining traditional knowledge with modern technology for natural remedies.
- Unani Products Division: Revenue from traditional Unani healing products using centuries-old formulations with herbs and natural ingredients.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels2 records
Drug International Limited product offering
Product offeringCore offering
Drug International Limited researches, develops, and manufactures a broad portfolio of pharmaceutical products across key therapeutic categories including Oncology, Cardiology, Steroids, Vitamins, and Antibiotics. It also operates separate Herbal and Unani divisions producing natural and traditional remedies. Products are manufactured at WHO cGMP compliant facilities in Bangladesh and exported to healthcare providers in more than 37 countries.
Product overview
Drug International Limited is a pharmaceutical company with a diversified portfolio spanning multiple therapeutic areas. The core pharmaceutical products include oncology medications (Toposar, Dobixin, Mylostat, Sonib, Ontaxel-30, Epiruba-50, Mes-D), cardiovascular medications (Varox), steroids (Depomed, Foly Injection, Dezco), and vitamins (Foly). The company also operates specialized divisions for herbal products (Herbal Division) and traditional Unani medicines (Unani products), offering holistic wellness solutions alongside conventional pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Brands
- Herbal Division: Herbal products crafted using carefully selected medicinal plants and herbs, backed by extensive research and development.
- Unani
Products and services
- Toposar
Companies that use Drug International Limited
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Drug International Limited technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Drug International Limited partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights4 records
Drug International Limited competitors and assessment
Company assessmentDirect peers
- ACI Limited (Pharma Division): ACI operates a pharmaceutical manufacturing division in Bangladesh producing generics across multiple therapeutic categories for domestic and international markets, comparable to Drug International's business scope.
- Eskayef Pharmaceuticals Limited: Eskayef is a Bangladeshi pharmaceutical manufacturer with WHO cGMP certification producing finished dosage forms for both domestic and export markets, closely matching Drug International's profile.
- Square Pharmaceuticals Limited: Square is the largest pharmaceutical manufacturer in Bangladesh with WHO cGMP-certified facilities and broad export reach, making it a direct peer in the Bangladeshi generic pharma manufacturing and export category.
- Beximco Pharmaceuticals Limited: Beximco is a leading Bangladeshi generic pharmaceutical manufacturer exporting to 50+ countries with a similarly diversified therapeutic portfolio including oncology, cardiovascular, and antibiotics, making it the closest direct peer to Drug International.
- Renata Limited: Renata is a Bangladeshi pharmaceutical company producing finished formulations for domestic and international markets across similar therapeutic categories, comparable in scale and export orientation to Drug International.
- Healthcare Pharmaceuticals Limited: Healthcare Pharmaceuticals is a Bangladeshi generic manufacturer with WHO cGMP certification and export operations in oncology, cardiology, and other therapeutic areas overlapping with Drug International.
- Incepta Pharmaceuticals Limited: Incepta is a Bangladeshi pharmaceutical manufacturer with WHO cGMP-certified facilities and an export portfolio spanning multiple therapeutic areas, directly comparable to Drug International in scope and target markets.
Broad incumbents
- Cipla Limited: Cipla is a major Indian generic pharmaceutical company with strong presence in Africa and South Asia, directly overlapping with Drug International's export geographies and therapeutic categories.
- Sun Pharmaceutical Industries Limited: Sun Pharma is the largest Indian generic manufacturer with global export presence and broad therapeutic coverage; it serves as a broad incumbent competitor to Bangladeshi manufacturers like Drug International in emerging and regulated markets.
- Aurobindo Pharma Limited: Aurobindo is a large Indian generic manufacturer with extensive emerging-market export operations, comparable to Drug International as a competing generic exporter into Africa and Asia.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Drug International Limited social profiles
Digital presenceDrug International Limited compliance and trust
Trust signalCompliance3 records
Drug International Limited financial estimates
Financial estimateRevenue estimate
Valuation estimate
Drug International Limited leadership team
Management profileNumber of profiles
Drug International Limited funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Drug International Limited M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Drug International Limited
What does Drug International Limited do?
Drug International Limited researches, develops, and manufactures a broad portfolio of pharmaceutical products across key therapeutic categories including Oncology, Cardiology, Steroids, Vitamins, and Antibiotics. It also operates separate Herbal and Unani divisions producing natural and traditional remedies. Products are manufactured at WHO cGMP compliant facilities in Bangladesh and exported to healthcare providers in more than 37 countries.
Is Drug International Limited a public or private company?
Drug International Limited is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Drug International Limited founded?
Drug International Limited was founded in 1974. It employs 1 to 10 people.
Where is Drug International Limited based?
Drug International Limited is headquartered in Dhaka, Bangladesh, in the Asia region.
How does Drug International Limited make money?
Four revenue lines are on record. Pharmaceutical Manufacturing and Sales are the primary driver. The others are international Export, herbal Products Division and unani Products Division.
Who are Drug International Limited's main competitors?
Direct peers on record are ACI Limited (Pharma Division), Eskayef Pharmaceuticals Limited, Square Pharmaceuticals Limited, Beximco Pharmaceuticals Limited, Renata Limited, Healthcare Pharmaceuticals Limited and Incepta Pharmaceuticals Limited. Broad incumbents are Cipla Limited, Sun Pharmaceutical Industries Limited and Aurobindo Pharma Limited.
Does Drug International Limited have an API?
No public API is recorded for Drug International Limited.
What industry is Drug International Limited in?
Drug International Limited's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.